|Type||Public (Euronext: IPN)|
|Key people||Marc de Garidel (Chairman)|
Ipsen is a French pharmaceutical company headquartered in Paris, France. It primarily develops and markets medications used in oncology, endocrinology and the treatment of neuromuscular disorders. It is publicly traded on the Euronext Paris as part of the SBF 120 index.
Ipsen is a global speciality-driven pharmaceutical company with total sales exceeding €1.2 billion in 2012. Ipsen's ambition is to become a leader in speciality healthcare solutions for targeted debilitating diseases. Its development strategy is supported by 3 franchises: neurology, endocrinology and urology-oncology. Moreover, the Group has an active policy of partnerships. Ipsen's R&D is focused on its innovative and differentiated technological platforms, peptides and toxins.
The Beaufour family, which ranks as the 42nd richest family in France, still owns 68% of its share, and two of its members, Anne and Henri Beaufour, sit on its board of directors. Its chairman and chief executive officer is Marc de Garidel.
Board of directors
- Anne Beaufour.
- Henri Beaufour.
- Hervé Couffin.
- Martha Crawford.
- Antoine Flochel (Vice-Chairman).
- Gérard Hauser.
- Mayroy SA (represented by Philippe Bonhomme).
- Pierre Martinet.
- Christophe Vérot.
- Carol Xueref.
In 1983, Ipsen founded the Ipsen Foundation (Fondation Ipsen) with the help of the Fondation de France to track progress in biomedical research. It is headquartered in Boulogne-Billancourt, and its chairman is Yves Christen. It has organised 64 colloquia, and it has partnered with the World Health Organisation, the Fondation Nationale de Gérontologie, Harvard University, the Salk Institute for Biological Studies, the Massachusetts General Hospital, and the academic journals Nature and Cell.